Year 2020 / Volume 112 / Number 1
Original
Elevated high mobility group A2 expression in liver cancer predicts poor patient survival

27-33

DOI: 10.17235/reed.2019.6365/2019

Yue-Chen Zhao, Yan Jiao, Yan-Qing Li, Zhuo Fu, Zhao-Ying Yang, Miao He,

Abstract
Background: liver cancer is a malignant tumor with a high morbidity and mortality that endangers human health. High mobility group A2 (HMGA2) is a chromosome associated protein that participates in embryogenesis, tissue development, tumorigenesis and development. Objective: to explore the relationship between HMGA2 expression and the clinicopathological parameters and survival of liver cancer patients using The Cancer Genome Atlas Liver Hepatocellular Carcinoma (HCC) data. Methods: RNA-sequencing data and the corresponding clinical characteristics of the patients were downloaded from the Atlas database. The Chi-squared test was used to assess the relationship between HMGA2 expression and clinical variables. Cox regression analysis was used to compare survival rates between the high- and low-expressing groups; the p-values and Kaplan-Meier survival curves were compared using the log-rank test. Results: RNA-seq data from 373 cases of liver cancer cases were analyzed. HMGA2 was overexpressed in liver cancer and significantly associated with gender (p = 0.0357), T classification (p = 0.0063), clinical classification (p = 0.0026) and overall survival (p = 0.0386). According to the multivariate analysis, HMGA2 could independently predict overall survival in liver cancer. Conclusions: HMGA2 independently predicts poor prognosis in liver cancer and serves as a molecular marker to determine disease prognosis.
Share Button
New comment
Comments
No comments for this article
References
1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Wang HL, Mo DC, Zhong JH, et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 2019;98:e14498.
3. Diaz-Gonzalez A, Forner A, Rodriguez de Lope C, et al. New challenges in clinical research on hepatocellular carcinoma. Rev Esp Enferm Dig 2016;108:485-93.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
5. Yang D, Tewary P, de la Rosa G, et al. The alarmin functions of high-mobility group proteins. Biochim Biophys Acta 2010;1799:157-63.
6. Zhang Q, Wang Y. High mobility group proteins and their post-translational modifications. Biochim Biophys Acta 2008;1784:1159-66.
7. Jakobiec FA, Stagner AM, Eagle RC, Jr., et al. Unusual pleomorphic adenoma of the lacrimal Gland: Immunohistochemical demonstration of PLAG1 and HMGA2 oncoproteins. Surv Ophthalmol 2017;62:219-226.
8. Qin Y, Niu Y, Liu F. Research progress of relationship between HMGA2 and tumors. Zhonghua Bing Li Xue Za Zhi 2014;43:65-7.
9. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
10. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-9.
11. Fedele M, Palmieri D, Fusco A. HMGA2: A pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol 2010;326:19-24.
12. Xing F, Song Z, He Y. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2. Biol Res 2018;51:50.
13. Ye ZH, Gui DW. miR539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2. Mol Med Rep 2018;17:5611-5618.
14. Chang HY, Ye SP, Pan SL, et al. Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer. Theranostics 2017;7:3889-3900.
15. Wang Y, Chen F, Zhao M, et al. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem 2017;292:15395-15407.
16. Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data. PLoS One 2014;9:e106397.
17. Wu L, Wang Z, Lu R, et al. Expression of high mobility group A2 is associated with poor survival in hepatocellular carcinoma. Pathol Oncol Res 2012;18:983-7.
18. Sgarra R, Maurizio E, Zammitti S, et al. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res 2009;8:2978-89.
19. Zhang N, Jiang W. Long noncoding RNA DANCR promotes HMGA2mediated invasion in lung adenocarcinoma cells. Oncol Rep 2019;41:1083-1090.
20. Tsubakihara Y, Moustakas A. Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor beta. Int J Mol Sci 2018;19.
21. Zha L, Zhang J, Tang W, et al. HMGA2 elicits EMT by activating the Wnt/beta-catenin pathway in gastric cancer. Dig Dis Sci 2013;58:724-33.
22. Watanabe S, Ueda Y, Akaboshi S, et al. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68.
23. Kou B, Liu W, Tang X, et al. HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-beta/Smad2 signaling pathway. Oncol Rep 2018;39:101-108.
24. Belge G, Radtke A, Meyer A, et al. Upregulation of the high mobility group AT-hook 2 gene in acute aortic dissection is potentially associated with endothelial-mesenchymal transition. Histol Histopathol 2011;26:1029-37.
25. Che N, Zhao XL, Sun T, et al. The role of Twist1 in hepatocellular carcinoma angiogenesis: a clinical study. Hum Pathol 2011;42:840-7.
26. Zhang H, Tang Z, Deng C, et al. HMGA2 is associated with the aggressiveness of tongue squamous cell carcinoma. Oral Dis 2017;23:255-264.
27. Esmailzadeh S, Mansoori B, Mohammadi A, et al. siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma. J Gastrointest Cancer 2017;48:156-163.
28. Natarajan S, Hombach-Klonisch S, Droge P, et al. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia 2013;15:263-80.
29. Liu Z, Wu K, Yang Z, et al. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients. Mol Cell Biochem 2015;409:155-62.
30. Strell C, Norberg KJ, Mezheyeuski A, et al. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer 2017;117:65-77.
31. Sun J, Sun B, Sun R, et al. HMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinoma. Sci Rep 2017;7:2229.
32. Sahengbieke S, Wang J, Li X, et al. Circulating cell-free high mobility group AT-hook 2 mRNA as a detection marker in the serum of colorectal cancer patients. J Clin Lab Anal 2018;32:e22332.
33. Mei LL, Wang WJ, Qiu YT, et al. miR-125b-5p functions as a tumor suppressor gene partially by regulating HMGA2 in esophageal squamous cell carcinoma. PLoS One 2017;12:e0185636.
34. Li H, Zhao L, Zhang Z, et al. Roles of microRNA let-7b in papillary thyroid carcinoma by regulating HMGA2. Tumour Biol 2017;39:1010428317719274.
35. Li XX, Di X, Cong S, et al. The role of let-7 and HMGA2 in the occurrence and development of lung cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2018;22:8353-8366.
1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. DOI:10.3322/caac.20073
2. Wang HL, Mo DC, Zhong JH, et al. Systematic review of treatment strategy for recurrent hepatocellular carcinoma: Salvage liver transplantation or curative locoregional therapy. Medicine (Baltimore) 2019;98:e14498. DOI:10.1097/MD.0000000000014498
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. DOI:10.3322/caac.20107
4. Diaz-Gonzalez A, Forner A, Rodriguez de Lope C, et al. New challenges in clinical research on hepatocellular carcinoma. Rev Esp Enferm Dig 2016;108:485-93. DOI:10.17235/reed.2015.4012/2015
5. Yang D, Tewary P, de la Rosa G, et al. The alarmin functions of high-mobility group proteins. Biochim Biophys Acta 2010;1799:157-63. DOI:10.1016/j.bbagrm.2009.11.002
6. Zhang Q, Wang Y. High mobility group proteins and their post-translational modifications. Biochim Biophys Acta 2008;1784:1159-66. DOI:10.1016/j.bbapap.2008.04.028
7. Jakobiec FA, Stagner AM, Eagle RC, Jr., et al. Unusual pleomorphic adenoma of the lacrimal Gland: Immunohistochemical demonstration of PLAG1 and HMGA2 oncoproteins. Surv Ophthalmol 2017;62:219-226. DOI:10.1016/j.survophthal.2016.08.001
8. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
9. Rogalla P, Drechsler K, Frey G, et al. HMGI-C expression patterns in human tissues. Implications for the genesis of frequent mesenchymal tumors. Am J Pathol 1996;149:775-9.
10. Fedele M, Palmieri D, Fusco A. HMGA2: A pituitary tumour subtype-specific oncogene? Mol Cell Endocrinol 2010;326:19-24. DOI:10.1016/j.mce.2010.03.019
11. Liu Z, Wu K, Yang Z, et al. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients. Mol Cell Biochem 2015;409:155-62. DOI:10.1007/s11010-015-2521-0
12. Strell C, Norberg KJ, Mezheyeuski A, et al. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer 2017;117:65-77. DOI:10.1038/bjc.2017.140
13. Sahengbieke S, Wang J, Li X, et al. Circulating cell-free high mobility group AT-hook 2 mRNA as a detection marker in the serum of colorectal cancer patients. J Clin Lab Anal 2018;32:e22332. DOI:10.1002/jcla.22332
14. Li XX, Di X, Cong S, et al. The role of let-7 and HMGA2 in the occurrence and development of lung cancer: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2018;22:8353-8366. DOI:10.26355/eurrev_201812_16533
15. Team RDCJC. R : A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2009;14:12-21.
16. Wickham H. Ggplot2 :elegant graphics for data analysis. Journal of the Royal Statistical Society 2011;174:245–246.
17. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77. DOI:10.1186/1471-2105-12-77
18.Therneau TM, Grambsch PM, Modeling Survival Data: Extending the Cox Model, Springer, New York, 2000.
19. Jiao Y, Fu Z, Li Y, et al. High EIF2B5 mRNA expression and its prognostic significance in liver cancer: a study based on the TCGA and GEO database. Cancer Manag Res 2018;10:6003-6014. DOI:10.2147/cmar.S185459
20. Jiao Y, Fu Z, Li Y, et al. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One 2019;14:e0211291. DOI:10.1371/journal.pone.0211291
21. Jiao Y, Li Y, Lu Z, et al. High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer. Dig Dis Sci 2019;64:137-143. DOI:10.1007/s10620-018-5315-x
22. Jiao Y, Li Y, Jiang P, et al. PGM5: a novel diagnostic and prognostic biomarker for liver cancer. PeerJ 2019;7:e7070. DOI:10.7717/peerj.7070
23. Jiao Y, Li Y, Liu S, et al. ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer. Onco Targets Ther 2019;12:4141-4152. DOI:10.2147/ott.S201675
24. Wu L, Wang Z, Lu R, et al. Expression of high mobility group A2 is associated with poor survival in hepatocellular carcinoma. Pathol Oncol Res 2012;18:983-7. DOI:10.1007/s12253-012-9514-z
25. Sgarra R, Maurizio E, Zammitti S, et al. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res 2009;8:2978-89. DOI:10.1021/pr900087r
26. Zhang N, Jiang W. Long noncoding RNA DANCR promotes HMGA2mediated invasion in lung adenocarcinoma cells. Oncol Rep 2019;41:1083-1090. DOI:10.3892/or.2018.6897
27. Xing F, Song Z, He Y. MiR-219-5p inhibits growth and metastasis of ovarian cancer cells by targeting HMGA2. Biol Res 2018;51:50. DOI:10.1186/s40659-018-0199-y
28. Tsubakihara Y, Moustakas A. Epithelial-Mesenchymal Transition and Metastasis under the Control of Transforming Growth Factor beta. Int J Mol Sci 2018;19. DOI:10.3390/ijms19113672
29. Watanabe S, Ueda Y, Akaboshi S, et al. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68. DOI:10.2353/ajpath.2009.080523
30. Belge G, Radtke A, Meyer A, et al. Upregulation of the high mobility group AT-hook 2 gene in acute aortic dissection is potentially associated with endothelial-mesenchymal transition. Histol Histopathol 2011;26:1029-37. DOI:10.14670/HH-26.1029
31. Esmailzadeh S, Mansoori B, Mohammadi A, et al. siRNA-Mediated Silencing of HMGA2 Induces Apoptosis and Cell Cycle Arrest in Human Colorectal Carcinoma. J Gastrointest Cancer 2017;48:156-163. DOI:10.1007/s12029-016-9871-z
32. Natarajan S, Hombach-Klonisch S, Droge P, et al. HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia 2013;15:263-80. DOI:10.1593/neo.121988
33. Sun J, Sun B, Sun R, et al. HMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinoma. Sci Rep 2017;7:2229. DOI:10.1038/s41598-017-02494-6
34. Mei LL, Wang WJ, Qiu YT, et al. miR-125b-5p functions as a tumor suppressor gene partially by regulating HMGA2 in esophageal squamous cell carcinoma. PLoS One 2017;12:e0185636. DOI:10.1371/journal.pone.0185636
35. Li H, Zhao L, Zhang Z, et al. Roles of microRNA let-7b in papillary thyroid carcinoma by regulating HMGA2. Tumour Biol 2017;39:1010428317719274. DOI:10.1177/1010428317719274
Related articles

Digestive Diseases Image

Inflammatory pseudotumor-like follicular dendritic cell sarcoma of the liver

DOI: 10.17235/reed.2020.7602/2020

Original

Can we optimize CEA as a response marker in rectal cancer?

DOI: 10.17235/reed.2020.7321/2020

Editorial

The right colon challenge

DOI: 10.17235/reed.2018.5544/2018

Letter to the Editor

Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity

DOI: 10.17235/reed.2017.4997/2017

Letter to the Editor

Pancreatic neuroendocrine tumors. Prognostic factors

DOI: 10.17235/reed.2017.5109/2017

Editorial

Pancreas neuroendocrine tumors - not so rare or benign

DOI: 10.17235/reed.2016.4672/2016

Citation tools
Zhao Y, Jiao Y, Li Y, Fu Z, Yang Z, He M, et all. Elevated high mobility group A2 expression in liver cancer predicts poor patient survival . 6365/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 509 visits.
This article has been downloaded 116 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 01/05/2019

Accepted: 25/07/2019

Online First: 11/12/2019

Published: 10/01/2020

Article revision time: 78 days

Article Online First time: 224 days

Article editing time: 254 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology